Orphan Drug Insights Journal

Orphan Drug Designation by the European Medicines Agency (EMA ODD)

Fri, 22 May 2026 16:55:34 GMT

For biotech and pharmaceutical companies developing therapies for rare diseases, securing orphan drug designation in Europe is one of the most consequential regulatory milestones in a program's lifecycle. It unlocks ten years of market exclusivity, fee reductions, protocol assistance, and direct access to the European Medicines Agency (EMA) for ongoing scientific guidance. But the EMA's criteria for orphan designation are not the same as the FDA's, and the application process is, in several important ways, more complex.

At Only Orphans Cote, we help global biotech and pharmaceutical companies secure EMA orphan drug designation. This article walks through what every sponsor should know about the European pathway and how it differs from the U.S. one.

What to Know About Orphan Drug Designation in Europe

The European Medicines Agency is a decentralised agency of the European Union responsible for evaluating the safety and efficacy of medicines in Europe. Unlike the FDA, the EMA does not have the authority to approve medications directly. It issues guidance and makes authorization recommendations on medicinal products that the European Commission ultimately approves for marketing in the EU. For orphan medicines, this two-step structure is reflected in the designation process itself.

EMA Orphan Designation Criteria

To qualify for orphan designation under EMA, a medicine must meet a defined set of criteria. According to the EMA:

The medicine must be intended for the treatment, prevention, or diagnosis of a disease that is life-threatening or chronically debilitating.
The prevalence of the condition in the EU must not be more than 5 in 10,000No satisfactory method of diagnosis, prevention, or treatment of the condition concerned can be authorised in the EU; or, if such a method exists, the medicine must be of significant benefit to those affected by the condition.

The "significant benefit" requirement is one of the most important features of the EMA pathway, and one of the most frequently underestimated by sponsors who arrive from the U.S. system. In the U.S., showing significant benefit is only required if the same drug has been approved for the same orphan indication. In the EU, all products need to justify the significant benefit over any authorised product in the same condition. This benefit may be related to improvements in clinical outcomes or to patient care, such as ease of use. A case for "the possibility of significant benefit" can often be made at the designation stage based on development data, but if that benefit has not been demonstrated by the time of the pivotal studies, it is a common reason for withdrawal of orphan designation at the marketing authorization review. Building the significant-benefit case into the development plan from the start, not at the end, is how sponsors avoid losing the designation when it matters most.

Who Reviews the Application

Applications for orphan designation are examined by the EMA's Committee for Orphan Medicinal Products (COMP), supported by a network of experts the Committee has built. Each application is assigned two coordinators: one member of the COMP and one scientific administrator from the EMA secretariat.

The COMP adopts an opinion by day 90 of the procedure and forwards it to the European Commission, which then issues a decision within 30 days of receipt. If the COMP's opinion is negative, the sponsor can appeal.

A Cautionary Case Study: Tissue-Agnostic Indications

A useful example of how the EMA's stricter "distinct condition" definition plays out in practice is larotrectinib (sold as Vitrakvi), a targeted therapy for solid tumours with NTRK gene fusions.

In the United States, the FDA granted orphan designation for the treatment of solid tumours with NTRK-fusion proteins — a single, tissue-agnostic designation. In the EU, the EMA had granted orphan designation for four separate, tissue-specific indications: salivary gland cancer, soft tissue sarcoma, glioma, and papillary thyroid cancer. At the time of the marketing authorization review, the sponsor formally withdrew all four of those EMA orphan designations. The withdrawal assessment report noted that the EMA had informed the sponsor that a tissue-independent therapeutic indication could not be considered to be within the scope of a limited number of orphan designations covering separate tumor types.

The lesson for sponsors developing biomarker-driven or tissue-agnostic therapies is that the EMA's definition of "condition" is materially different from the FDA's, and a strategy that works in the U.S. may need to be rethought entirely for the EU.

How to Apply for EMA Orphan Designation

All submissions for orphan designation are made via EMA's secure online IRIS platform. The EMA gives sponsors two options:

Submit directly through IRIS, with no pre-submission meeting required.
Request a pre-submission meeting with the EMA, typically held via teleconference, at least two months before the planned submission date.

Pre-submission meetings are not mandatory, but the EMA strongly encourages them. The Agency's own guidance notes that the 90-day evaluation procedure has a fixed duration and cannot be lengthened to accommodate gaps in the data. Experience has shown that pre-submission meetings have a positive impact on the success rate of applications.

One practical advantage of the EU pathway is that sponsors have more control over the timing of their submission than is often appreciated. The COMP holds monthly plenary meetings on a calendar published roughly two years in advance, which means sponsors can plan their notification, pre-submission discussions, and final submission around the specific evaluation meeting they want to target.

Incentives for EMA Orphan Designation

Sponsors who obtain EMA orphan designation benefit from:

Protocol assistance , a form of scientific advice specifically for designated orphan medicines.
Ten years of market exclusivity once the medicine is on the market.
Fee reductions for regulatory activities, the size of which depends on the sponsor's status (with additional reductions available to micro, small, and medium-sized enterprises) and the type of service required.

Sponsors must submit an annual report to EMA summarising the status of development of the designated medicine.

EMA vs. FDA for Orphan Drug Designation

The FDA and EMA both offer orphan designation pathways with the same underlying goal: incentivising development of medicines for rare diseases. The criteria, however, are not identical, and several differences materially affect how sponsors should plan a global program.

How Only Orphans Cote Supports Sponsors Pursuing EMA Designation

Only Orphans Cote is a regulatory affairs consulting firm headquartered in Cambridge, Massachusetts, that exclusively works on orphan drug regulatory affairs. The firm is led by Dr. Timothy Cote, former Director of the FDA's Office of Orphan Products Development, who personally decided on 1,400 orphan drug designation applications during his tenure at the Agency. When Dr. Cote was the Director of OOPD, he met with the COMP/EMA approximately every six months, which gave him deep insight into EMA’s thinking and expectations regarding EMA ODD applications.

For sponsors pursuing EMA orphan designation, Only Orphans Cote offers:

A free initial data review to evaluate EMA orphan designation readiness before a sponsor invests in a full application.
Application writing for EMA orphan drug designation
Epidemiology and prevalence support to prepare robust prevalence data for the EU patient population.
Therapeutic advantage articulation to help sponsors meet the EMA's "significant benefit" requirement.
Annual report and post-designation activities to ensure ongoing compliance with EMA's reporting requirements.
A wholly owned subsidiary in Dublin, allowing us to serve as your agent for all EMA submissions and communications for non-EU clients.

Only Orphans Cote also supports clients on the European side of the process. EMA orphan designation applications must be submitted by a sponsor established in the European Economic Area, which means non-EU biotechs typically need an EU-based legal presence or representative to file. Our team is set up to support European clients and to help non-EU sponsors navigate that requirement, so the regulatory pathway does not stall on a structural detail.

Conclusion

EMA orphan drug designation is one of the most valuable regulatory tools available to companies developing therapies for rare diseases in Europe. It carries longer market exclusivity than the FDA equivalent, layered incentives, and direct engagement with the EMA. It also carries a steeper bar, particularly around the "significant benefit" requirement and the EMA's stricter definition of condition.

For sponsors who plan their EMA strategy carefully and present a complete, well-supported application, the rewards are substantial. For those who don't, the long timeline and complicated review process leaves little room to correct the course.

If you're preparing for an EMA orphan drug designation application or building a parallel FDA/EMA strategy, the team at Only Orphans Cote can help you assess readiness, frame your case, and submit a strong application from the start. Request a Quote to start a conversation with our team.

FAQs

What is orphan drug designation at the EMA?

EMA orphan drug designation is a regulatory status granted to medicines intended for the treatment, prevention, or diagnosis of life-threatening or chronically debilitating rare diseases in the EU. To qualify, the condition must affect no more than 5 in 10,000 people in the EU, and the medicine must offer significant benefit over any existing authorised treatment, or fill an unmet need where none exists.

How long does the EMA orphan designation process take?

The EMA's Committee for Orphan Medicinal Products (COMP) evaluates applications over a fixed 90-day procedure and adopts an opinion by day 90. The European Commission then issues its decision within 30 days of receipt. Pre-submission meetings should be requested at least two months before the planned submission date.

What is the main difference between FDA and EMA orphan drug designation?

The most significant difference is the EMA's "significant benefit" and “seriousness”. If an authorised treatment for the condition already exists in the EU, an EMA applicant must demonstrate that the new medicine offers a clinical or patient-care advantage. The FDA does not require this. The EMA also offers ten years of market exclusivity compared with the FDA's seven, and applies a stricter definition of "condition," particularly regarding biomarker-defined subtypes.

How do sponsors apply for EMA orphan designation?

All applications are submitted through the EMA's secure IRIS platform. Sponsors can submit directly or, as the EMA strongly encourages, request a pre-submission meeting with the Agency at least two months before the planned submission. Application templates and procedural guidance are available on the EMA website.

Can a company apply for FDA and EMA orphan designation at the same time?

Yes.

What incentives come with EMA orphan designation?

Designated orphan medicines benefit from protocol assistance, ten years of market exclusivity after approval (with an additional two years available for medicines that complete an approved paediatric investigation plan), and fee reductions for regulatory activities. Micro, small, and medium-sized enterprises receive further support through EMA's SME office.

How does Only Orphans Cote help with EMA orphan drug designation?

Only Orphans Cote helps biotech and pharmaceutical companies prepare and submit EMA orphan drug designation applications, supports the development of prevalence data and significant-benefit arguments, manages annual reporting, and offers a free initial data review to evaluate readiness.

Expedited Programs Beyond Orphan Designation

Mon, 11 May 2026 17:04:40 GMT

When developing a drug for a rare disease, orphan drug designation is often the first regulatory milestone on the list. But it is not the only incentive the FDA has created to help promising therapies reach patients faster. For sponsors navigating the complex landscape of drug development, understanding the full scope of FDA expedited programs is an important part of building a successful regulatory strategy.

At Only Orphans Cote, we work directly with drug sponsors to navigate FDA and EMA regulatory requirements, from data assessment through submission. Under the leadership of Dr. Timothy Cote, former Director of the FDA's Office of Orphan Product Development, our team brings firsthand regulatory experience to every client engagement. Dr. Cote personally decided on 1,400 orphan designation applications and wrote about 900 orphan designations as a consultant.

Submissions for Expedited Programs is one of the core services we offer. Beyond orphan designation, there are four FDA programs designed to accelerate drug development and approval for serious conditions with unmet medical needs. Understanding these programs, and whether your drug may qualify for one or more of them, can meaningfully shape your development timeline.

Four Expedited Drug Approval Programs

Not all drug approvals follow the FDA's standard review process. Drug therapies that address unmet medical needs, treat serious or life-threatening conditions, or show a significant advantage over current therapies may be eligible for one or more of the FDA's four expedited review programs. These programs are designed to accelerate the approval process and make therapies available to patients more quickly, provided that the benefits justify the risks. The four programs are Priority Review, Accelerated Approval, Fast Track, and Breakthrough Therapy.

1. Priority Review

Priority Review shortens the FDA's standard review timeline from 10 months to 6 months. To be eligible, a drug must treat a serious condition and provide a significant improvement in the safety or effectiveness of the treatment, diagnosis, or prevention of that condition compared to existing treatments.

Drug sponsors request Priority Review at the time of submitting either a New Drug Application (NDA) or a Biologics License Application (BLA). There is also a second route: Priority Review Vouchers. These vouchers are awarded to sponsors who develop treatments for neglected tropical diseases and rare pediatric diseases , can be redeemed by the sponsor or sold to another sponsor to use for the same purpose.

2. Accelerated Approval

The Accelerated Approval pathway allows the FDA to approve a drug based on a surrogate endpoint or intermediate endpoint, rather than waiting for traditional primary clinical outcomes such as overall survival or progression-free survival. Surrogate endpoints can include lab values, imaging results, physical signs, or other scientifically accepted measures, and serve as a proxy for clinical benefit. Because it often takes years for primary endpoints to mature, this pathway allows promising drugs to reach patients sooner.

To qualify, a drug must treat a serious condition, provide a meaningful advantage over available therapies, and demonstrate a surrogate endpoint reasonably likely to predict clinical benefit. Sponsors typically explore the possibility of Accelerated Approval with the FDA early in the development process, often during the design of clinical trials. As a condition of approval, sponsors are required to complete post-marketing confirmatory trials to verify the predicted clinical benefit. If post-marketing studies don't verify the efficacy of the drug, approval can be revoked at the discretion of the FDA.

3. Fast Track Designation

Fast Track designation improves the efficiency of the drug development and review process by enabling rolling review. Under a standard submission, the FDA requires all segments of an NDA or BLA to be submitted before review begins. With Fast Track, the FDA can review portions of the application as they arrive, rather than waiting for the complete package. The program also facilitates more frequent communication between the drug sponsor and FDA reviewers during development, which can help address questions earlier and reduce delays.

Eligible drugs must treat a serious condition, and nonclinical or clinical data must demonstrate the potential to address an unmet medical need. In 2022, 32% of novel new drugs approved by the FDA's Center for Drug Evaluation and Research (CDER) had received Fast Track designation.

4. Breakthrough Therapy

Breakthrough Therapy designation is typically reserved for drugs treating life-threatening or debilitating disease states where preliminary clinical evidence indicates the drug may demonstrate substantial improvement over available therapies on a clinically significant endpoint. To be eligible, a drug must treat a serious condition and have substantial improvement on a clinically significant endpoint(s) over available therapies.

Breakthrough Therapy includes all of the benefits of Fast Track designation, plus organizational commitment from FDA senior managers to engage in intensive guidance throughout the clinical development process.

“You get extra love from the FDA,” as Timothy Cote puts it. Fast Track can be pursued with an open IND, making it an earlier and more accessible opportunity to engage the FDA and facilitate development. Breakthrough Therapy designation, by contrast, requires preliminary clinical evidence and a higher evidentiary bar. It is more subjective, selective and often more impactful, but also more difficult to obtain.

In practice, Fast Track is a valuable and strategic first step, while Breakthrough represents a more advanced designation with greater upside once sufficient data are available.

What Are the Benefits of Expedited Programs?

The four expedited programs share a common purpose: helping innovative drugs for serious unmet needs reach patients faster. A review published in the Journal of Personalized Medicine (Kantor and Haga, 2021) analyzed all FDA-approved new molecular entities (NMEs) between 2011 and 2017 and found that the majority of approved NMEs were associated with at least one expedited approval or FDA review pathway. Understanding both the advantages and the limitations of these programs is valuable for any sponsor building a regulatory strategy.

The Benefits

The most direct benefit is speed. Across the 250 NMEs approved between 2011 and 2017, Priority Review was the most commonly used program (applied to 133 drugs), while Accelerated Approval was the least common (applied to 32). The study found that expedited pathways were associated with faster times to approval, particularly in oncology, where companies frequently combined more than one expedited strategy.

Expedited programs also tend to attract more innovative therapies. More than one-third of all NMEs approved during the study period were first-in-class agents. The average number of expedited development programs per first-in-class drug reached 2.23, compared to 1.61 across all NMEs, suggesting that the most novel therapies benefit disproportionately from these mechanisms. The proportion of Breakthrough Therapy designation among first-in-class drugs was also higher than the overall rate.

Beyond speed, some programs offer structural development advantages. Breakthrough Therapy designation allows submission based on earlier phase trial data. Fast Track and Breakthrough Therapy both enable rolling review, reducing the bottleneck of a complete submission requirement. Accelerated Approval allows drugs to reach patients before primary endpoints have fully matured. And Priority Review compresses the FDA's review clock from 10 months to 6 months.

Conclusion

The FDA's four expedited programs, Priority Review, Accelerated Approval, Fast Track, and Breakthrough Therapy, exist alongside orphan drug designation as powerful tools to help qualifying drugs move through development and review more efficiently. For sponsors working on treatments for rare and serious conditions, understanding how these programs work and whether a drug may qualify is a critical part of regulatory planning.

At Only Orphans Cote, Submissions for Expedited Programs for rare disease drugs is one of our core regulatory services. With Dr. Timothy Cote at the helm, backed by decades of firsthand FDA experience and a record of supporting over 600 clients, our team is positioned to assess your drug's eligibility and guide your application with clarity, speed, and confidence.

Ready to explore whether your drug may qualify for an expedited program? Contact us today.

FAQs

What is the difference between orphan drug designation and the four expedited programs?

Orphan drug designation applies to drugs treating conditions that affect fewer than 200,000 people in the United States, and provides benefits including a partial tax credit for clinical trial expenditures, waived user fees, and seven years of marketing exclusivity. The four expedited programs (Priority Review, Accelerated Approval, Fast Track, and Breakthrough Therapy) are focused on accelerating the development and review process for drugs treating serious conditions with unmet medical needs. A drug can qualify for orphan designation and one or more expedited programs at the same time.

Can a drug qualify for more than one expedited program?

Yes. Drugs can qualify for more than one expedited program simultaneously. The analysis of 2011 to 2017 NME approvals found that the average number of expedited development and review programs per approved drug was 1.61 overall, rising to 2.23 for first-in-class drugs.

When should a sponsor request expedited designation?

The timing depends on the program. Fast Track and Breakthrough Therapy designations are typically requested during drug development, before the NDA or BLA is submitted. Breakthrough Therapy must be requested no later than the end of Phase II clinical trial meetings with the FDA. Priority Review is requested at the time of NDA or BLA submission. Accelerated Approval is typically explored early in the development process, often during the design of clinical trials.

What is a surrogate endpoint for Accelerated Approval purposes?

A surrogate endpoint is a measure used in clinical trials that is reasonably likely to predict a drug's clinical benefit, even though it does not directly measure patient outcomes like survival. Examples include lab values, imaging results, physical signs, and other scientifically accepted measures. Using a surrogate endpoint allows approval to proceed before full primary outcome data have matured.

A Win for Rare Pediatric Disease Drug Innovation: The RPDD & PRV Program Is Reauthorized Through 2029, and OOC Is Ready

Fri, 27 Mar 2026 16:03:26 GMT

February 3, 2026 was a significant day for the rare pediatric disease community. The Consolidated Appropriations Act of 2026 was signed into law, reauthorizing the Rare Pediatric Disease Designation Priority Review Voucher (RPDD PRV) program through September 30, 2029.

After a year of anxiety over the sunset, sponsors who have been building rare pediatric disease programs can once again treat PRV eligibility as a reliable planning assumption rather than an expiring hope. The window is now open, with a clear timeline, and the opportunity is significant.

At Only Orphans Cote (OOC), our CEO, Dr. Timothy Cote, was one of the legislators involved in the creation of the RPDD PRV program. Here is what the reauthorization means, why it matters, and how OOC can help you act on it.

What Are RPDD and PRV?

Rare Pediatric Disease Designation (RPDD) is granted by the U.S. FDA to drugs intended to treat or prevent serious or life-threatening diseases that primarily affect children and affect fewer than 200,000 patients in the United States. If a drug with RPDD is ultimately approved, the sponsor may receive a Priority Review Voucher (PRV), a transferable certificate that entitles the holder to request priority FDA review for any future drug application.

Importantly, the voucher can be sold to any other sponsor. This creates a secondary market where rare disease biotechs monetize their regulatory achievement, and large pharma companies purchase time-to-market advantages for their most lucrative pipelines. In practical terms, a PRV compresses the FDA review timeline from roughly ten months to about six months. That four-month acceleration is enormously valuable for large pharmaceutical companies racing to bring high-value drugs to market, which is why PRVs consistently trade in the $75 million to $150 million range, making them one of the most valuable non-dilutive assets in drug development.

A Program With Deep Roots, and OOC's Fingerprints on It

The PRV concept was first proposed in a landmark 2006 Health Affairs paper by Ridley, Grabowski, and Moe . Congress acted on it the following year, establishing the tropical disease PRV program in 2007 under the FDA Amendments Act (FDAAA) to incentivize treatments for neglected tropical diseases. The success of that model led policymakers to extend the mechanism to rare pediatric diseases through the FDA Safety and Innovation Act (FDASIA) of 2012, creating the RPDD PRV program we know today.

The program has been reauthorized before, in 2016 and again in 2020, each time for four additional years. The 2026 reauthorization follows that same pattern, extending it to September 30, 2029.

What makes OOC's perspective on this program genuinely singular is that our CEO, Dr. Timothy Cote, was one of the legislators involved in the creation of the RPDD PRV program. Dr. Cote is the former Director of the FDA Office of Orphan Products Development (OOPD), and is the only former Director of FDA/OOPD currently working as a regulatory consultant focused on orphan drug development.

The Numbers Speak for Themselves

The RPDD PRV program has been running for over a decade. The evidence of its impact is clear. According to an analysis from the National Organization for Rare Disorders (NORD), updated in November 2025:

63 RPDD Priority Review Vouchers have been awarded since the program's inception.
47 distinct rare pediatric diseases are represented among those approvals.
43 of those 47 diseases had no FDA-approved treatment before the PRV-earning drug was approved.

That last figure is the most powerful: the program has delivered first-ever treatments to 43 rare pediatric disease communities that previously had none. This is the PRV program working exactly as intended, using commercial incentives to drive innovation where the market alone would not.

How the PRV Market Actually Works

The ability to sell a Priority Review Voucher creates a powerful economic engine for small and mid-sized rare pediatric biotechs. Developing therapies for rare pediatric diseases often involves small patient populations and limited commercial markets, making it extremely difficult for early-stage companies to recover development costs through product revenue alone.

The PRV program addresses this by creating a secondary market for regulatory incentives. When a rare pediatric drug receives FDA approval and qualifies for a PRV, the sponsor can sell that voucher to another pharmaceutical company seeking to accelerate review of a future drug application. In practice:

Vouchers have historically sold for between approximately $50 million and $350 million.
Recent transactions have clustered in the $75 million to $150 million range.
For the rare disease biotech, this is immediate, non-dilutive capital to reinvest in pipeline development.
For the large pharma buyer, a PRV means a potential four-month head start to market on a high-value drug.

For blockbuster drugs expected to generate billions in annual revenue, launching even a few months earlier can yield enormous financial returns and competitive advantages, including beating rivals to market. This creates a mutually beneficial ecosystem that has become a significant and mature financial driver across the rare disease drug development landscape.

What the Consolidated Appropriations Act of 2026 Actually Does

The Consolidated Appropriations Act of 2026 , signed into law on February 3, 2026, delivers an important change for the rare disease community:

RPDD PRV Program Reauthorized Through September 30, 2029

The Act extends the program's sunset date, restoring certainty for any sponsor that had been building a rare pediatric disease pipeline with PRV eligibility in mind. FDA may award PRVs for qualifying drug approvals through September 30, 2029. The reauthorization also clarifies that there is no separate deadline by which a drug must receive its RPDD designation prior to the sunset date, an important technical point for sponsors whose designation timelines may span multiple years.

How OOC Helps You Navigate the RPDD PRV Lifecycle

Only Orphans Cote LLC is a consultancy dedicated to orphan drug development, led by Dr. Timothy Cote , one of the legislators involved in the creation of the RPDD PRV program, bringing direct policy and regulatory experience to sponsors pursuing rare disease incentives.

Our work provides sponsors with the direct policy and regulatory experience needed to successfully pursue RPDD and PRV eligibility, from initial assessment through approval.

We work with emerging biotechs and established pharmaceutical companies. Whether you are pursuing RPDD for the first time or repairing a previously unsuccessful submission, OOC brings unmatched regulatory and policy expertise rooted in helping shape the program itself.

Let's Talk

The reauthorization of the RPDD PRV program is a moment to act, not wait. While the Priority Review Voucher itself is awarded upon market approval, obtaining RPDD as early as possible is strategically crucial. The designation signals PRV potential, which can significantly strengthen fundraising and partnering discussions.The time to build your RPDD PRV strategy is now, not at approval.

Dr. Cote's direct experience as one of the legislators involved in the creation of the RPDD PRV program, combined with his background as former Director of FDA/OOPD, gives OOC a depth of knowledge in this space that is available to sponsors through our team. To learn more, visit Only Orphans Cote or reach out directly to our team .

Tropical Disease Priority Review Vouchers (PRVs) - How They Work

Mon, 23 Feb 2026 18:14:17 GMT

The Tropical Disease Priority Review Voucher is one of FDA's most valuable incentives for drug development. These vouchers have sold on the open market for approximately $160 million or more, creating a powerful financial incentive for sponsors developing treatments in diseases that affect the world's poorest populations.

What Is a Tropical Disease PRV?

A tropical disease PRV is a transferable voucher awarded by FDA when a sponsor gains approval for a drug or biologic that treats or prevents a qualifying tropical disease. The voucher allows its holder, whether the original sponsor or a purchaser, to convert a standard-review application into a priority review.

This cuts FDA review time from approximately 10 months down to 6 months. For blockbuster programs, those four months represent hundreds of millions in potential revenue, making PRVs extremely valuable even though they're earned through programs with minimal commercial potential.

How to Qualify for a Tropical Disease PRV

PRVs are awarded automatically at approval if your application meets all of the following criteria:

1. Treats or Prevents a Listed Tropical Disease

Your drug or biologic must address one of the tropical diseases specifically listed in the Federal Food, Drug, and Cosmetic Act (FD&C §524). The indication must clearly align with the listed disease, not a broader or adjacent condition.

2. Independently Qualifies for Priority Review

Your application must meet FDA's standard criteria for priority review on its own merits. This typically means demonstrating that your product, if approved, would represent a significant improvement in safety or effectiveness compared to existing therapies.

3. Contains No Previously Approved Active Ingredients

The application cannot contain an active ingredient, or salt or ester of an active ingredient, that has been previously approved by FDA. This ensures PRVs reward genuinely new therapies.

4. Includes a New Clinical Investigation (Post-2017 Applications)

For applications submitted after the FDA Reauthorization Act of 2017, at least one new clinical investigation must be essential to the approval. This prevents PRVs from being awarded for minor modifications or supplemental approvals.

5. Provides Required Attestations

The sponsor must submit attestations regarding global regulatory submissions and other requirements as specified under FDARA 2017.

Which Tropical Diseases Qualify?

FDA maintains a statutory list of tropical diseases eligible for PRV consideration. Examples include:

Infectious Diseases:

Tuberculosis
Malaria
Human African trypanosomiasis (sleeping sickness)
Leishmaniasis
Dengue fever
Chagas disease
Zika virus disease
Ebola and other filovirus diseases
Chikungunya
Rabies
Cryptococcal meningitis

Parasitic Diseases:

Dracunculiasis (Guinea worm disease)
Schistosomiasis
Lymphatic filariasis
Soil-transmitted helminth infections

FDA may add additional diseases to this list if they meet statutory criteria, specifically diseases that have no significant market in developed nations and disproportionately impact impoverished populations.

For a complete understanding of the PRV Program and incentives, contact us.

Why Tropical Disease PRVs Matter

The transferability of PRVs creates a unique incentive structure. Even if your tropical disease program has minimal commercial value in wealthy markets, the voucher itself represents significant financial return.

For original sponsors: The PRV can be sold to pharmaceutical companies developing high-revenue products in competitive markets, generating $100-200M+ in non-dilutive capital.

For purchasers: Months of accelerated review for a blockbuster drug can mean hundreds of millions in additional revenue and competitive advantage.

How Sponsors Should Evaluate PRV Eligibility

If you're developing a treatment for a tropical disease, ask these questions early in your development strategy:

Does your indication precisely match a listed tropical disease?
Will your product independently qualify for priority review? Consider the competitive landscape and whether your therapy represents a meaningful advance.
Is this a new molecular entity? Previously approved active ingredients disqualify the application.

No Separate Application Required

Unlike orphan drug designation, which requires a specific request, the PRV is awarded automatically at market approval if all criteria are met.

Common Misconceptions

Myth: PRVs are only valuable if you plan to use them yourself.
Reality: PRVs are transferable and have established market value, making them valuable even for small sponsors.

Myth: Tropical disease PRVs are the same as orphan designation.
Reality: These are distinct programs with different criteria, though some products may qualify for both. Learn about the differences in our orphan drug designation guide .

Get Expert Guidance

Understanding whether your tropical disease program qualifies for a PRV, and how to structure your development to maximize that opportunity, requires expertise in both FDA regulations and the real-world interpretation of PRV criteria.

Only Orphans Cote works with sponsors to evaluate PRV eligibility, design development strategies that align with PRV requirements, and navigate the regulatory pathway to approval. Our team, led by Dr. Tim Cote (former Director of FDA's Office of Orphan Products Development and former Country Director for Rwanda of Center for Disease Control ), has unparalleled experience in rare disease and tropical disease programs.

With a 95% first-attempt success rate for designation applications and decades of FDA experience, we understand exactly how to position your program for success.

Contact us to assess your tropical disease program's PRV potential, or explore our Orphan Minute video series for additional insights on rare disease regulatory strategies.

Frequently Asked Questions

What is a Tropical Disease Priority Review Voucher worth?

Tropical disease PRVs have historically sold on the open market for $100-200 million, with some transactions exceeding $150 million. The exact value fluctuates based on market conditions and the strategic value to potential purchasers.

Can I apply for a tropical disease PRV separately from my drug approval?

No. Unlike orphan drug designation, there is no separate PRV application. The voucher is awarded automatically at the time of approval if your application meets all statutory criteria. However, you should engage with FDA early in development to ensure your program remains aligned with PRV requirements.

Can a product qualify for both orphan designation and a tropical disease PRV?

Yes. Many tropical diseases affect fewer than 200,000 patients in the United States and would qualify for orphan designation. Some products may be eligible for both incentive programs, though they serve different purposes. Learn more about orphan drug designation eligibility.

What happens if my product doesn't qualify for priority review on its own merits?

Priority review qualification is a mandatory requirement for receiving a tropical disease PRV. If your application doesn't independently meet priority review criteria (demonstrating significant improvement over existing therapies), you will not receive a PRV even if treating a listed tropical disease.

Are tropical disease PRVs transferable?

Yes. PRVs can be sold or transferred to other sponsors. This transferability is what creates their significant market value and makes them attractive even for sponsors working on programs with limited commercial potential.

What's the difference between a tropical disease PRV and a rare pediatric disease PRV?

These are separate voucher programs with different qualifying conditions. Tropical disease PRVs apply to specific listed diseases affecting impoverished populations globally, while rare pediatric disease PRVs apply to serious or life-threatening diseases primarily affecting children (under 18) and affecting fewer than 200,000 patients in the U.S. Please contact us to learn more about the reauthorization of the RPDD program.

When should I start planning for PRV eligibility in my development program?

As early as possible. PRV eligibility should be considered during program design and clinical development planning. Early engagement ensures your regulatory strategy, indication definition, and clinical trial design all support PRV qualification. Contact our team to evaluate your program's PRV potential.

FDA Orphan Drug Designation for Rare Cancers: U.S. Eligibility Guide

Mon, 12 Jan 2026 02:42:16 GMT

Understanding FDA Incentives for Rare Conditions - Eligible Cancers

For sponsors developing treatments for rare cancers, FDA's Orphan Drug Designation (ODD) offers powerful incentives that can transform your development strategy. These benefits include tax credits, fee waivers, market exclusivity, and accelerated pathways, but only if you understand which cancers actually qualify.

The Rare Cancer Landscape: Broader Than You Think

Dr. Tim Cote, former Director of FDA's Office of Orphan Products Development (OOPD), often reminds sponsors of a surprising fact about cancer prevalence:

"If I look down the microscope, I can see about 900 different kinds of cancers. There's only about 12 that are common, the rest are rare."

While common solid tumors dominate public awareness and research funding, the vast majority of cancers qualify as rare diseases under FDA's orphan designation criteria.

How FDA Determines If a Cancer Is "Rare"

FDA doesn't rely on lay definitions or broad cancer categories. For orphan designation purposes, the agency evaluates whether a cancer represents a distinct disease entity based on:

Pathogenesis – the underlying biological mechanisms
Course and prognosis – how the disease develops and typical outcomes
Response to treatment – therapeutic patterns and outcomes
WHO classifications – standardized international disease definitions
The drug's mechanism of action – how your specific therapy targets the disease

This scientific approach means FDA has evolved its thinking on certain cancers over time.

Which Cancers Typically Qualify as Rare?

According to Dr. Cote, these cancers generally qualify for FDA orphan designation:

Rare Cancers:

Glioblastoma multiforme
Esophageal cancer
Gastric cancer
Pancreatic cancer
Hepatocellular carcinoma
Small-cell lung cancer
Sarcomas
Most leukemias and lymphomas
Uveal melanoma

Common Cancers (Generally Don't Qualify):

Colorectal cancer
Head and neck cancer
Prostate cancer
Melanoma
Non-small cell lung cancer (though some subsets may qualify)
Breast cancer (including triple negative breast cancer)
Ovarian cancer

The Critical U.S.-Only Prevalence Rule: The Most Overlooked Opportunity

This is the single most important factor sponsors miss when evaluating orphan eligibility.

FDA's orphan drug designation eligibility is determined exclusively by U.S. patient population . Global disease burden is completely irrelevant to the calculation. The threshold is 200,000 patients in the United States, that's it.

Why This Matters: Globally Common Cancers May Still Qualify

Many sponsors developing treatments for cancers that are highly prevalent in Asia, Africa, Latin America, or other regions automatically assume they don't qualify for FDA orphan designation. This is a costly mistake.

The reality: If fewer than 200,000 patients in the United States have the disease, you may qualify for orphan designation, regardless of whether millions of patients worldwide are affected.

Real-World Examples of This Overlooked Opportunity

Consider these scenarios where sponsors frequently miss ODD eligibility:

Gastric cancer is extremely common in East Asia, with high incidence rates in Japan, Korea, and China. However, in the United States, gastric cancer remains relatively rare and may qualify for orphan designation depending on the specific indication.

Hepatocellular carcinoma (HCC) is highly prevalent in regions with endemic hepatitis B, particularly in sub-Saharan Africa and East Asia. Despite this global burden, HCC qualifies as a rare disease in the U.S. market.

Certain infection-associated cancers linked to parasites, viruses, or bacteria common in tropical regions may affect millions globally but remain rare in the American population.

Esophageal cancer subtypes show dramatically different geographic patterns, with some forms common in certain regions but rare in the United States.

The Strategic Implication

If you're developing a cancer therapy with a U.S. regulatory strategy, do not assume global prevalence data disqualifies you from orphan benefits. The U.S. patient count is what matters, and many internationally significant cancers remain below the 200,000-patient threshold in America.

This distinction can be the difference between:

A standard development pathway vs. one with substantial regulatory and financial advantages
Paying ~$4.5M in PDUFA fees vs. receiving a complete waiver
Standard market competition vs. 7 years of orphan exclusivity
Funding your clinical trials entirely out-of-pocket vs. receiving tax credits

What Orphan Designation Unlocks

If your cancer subtype, or the population defined by your drug's mechanism of action, affects fewer than 200,000 patients in the U.S., your therapy may qualify for:

Market exclusivity – 7 years of orphan exclusivity upon approval
Fee waiver – Approximately $4.5M PDUFA fee waived
Tax credits – Credit on U.S. clinical trial costs
PREA Exemption – Exempt from Pediatric Research Equity Act (PREA) requirements
Grant eligibility – Access to FDA grants through OOPD
Investor confidence – Stronger positioning for fundraising and partnerships

Learn more about orphan drug designation benefits and the application process.

Common Mistakes Sponsors Make

Mistake #1: Assuming a cancer common in their home country or development region is too common for U.S. orphan designation.

Mistake #2: Using global prevalence statistics instead of U.S.-specific epidemiology data.

Mistake #3: Overlooking that metastatic cancers, specific molecular subtypes, or treatment-resistant populations may qualify separately.

Work With Experts Who Know FDA from the Inside

Navigating whether your cancer subtype qualifies as a distinct orphan disease requires understanding FDA's real-world interpretation, not just reading the statute.

Only Orphans maintains a 95% first-attempt success rate for orphan designation applications, thanks to decades of experience within FDA's Office of Orphan Products Development.

Dr. Tim Cote and the team at Only Orphans have been responsible for granting orphan designation to more products than anyone else in history. We understand exactly how FDA evaluates cancer indications and can help you identify opportunities others miss.

If you're developing a product for a rare cancer or another neglected condition, contact us to evaluate eligibility and prepare a compelling submission.

Frequently Asked Questions

Does global prevalence matter for FDA orphan designation?

No. FDA calculates orphan eligibility based solely on the U.S. patient population. Even if a cancer affects millions of people worldwide, it may still qualify for orphan designation if fewer than 200,000 patients in the United States have the disease.

Can a subset of a common cancer qualify for orphan designation?

Yes. If your drug's mechanism of action targets a specific molecular subtype, genetic mutation, treatment-resistant population, or other defined subset that affects fewer than 200,000 U.S. patients, you may qualify even if the broader cancer category is common. However, there are many unwritten rules where FDA/OOPD has broad discretion in determining what constitutes a distinct disease or indication. For example, triple negative breast cancer is relatively rare, but it is generally considered part of the broader breast cancer category, which is common. If you are developing a therapy for a rare subset of a common disease, we recommend speaking with us early to assess whether it may qualify as a valid orphan subset.

What if my cancer is common in some countries but rare in the U.S.?

This is actually one of the most overlooked orphan designation opportunities. Many cancers that are highly prevalent in Asia, Africa, or Latin America remain rare in the United States and fully qualify for FDA orphan benefits.

What's the difference between orphan designation and orphan drug approval?

Orphan designation is granted during development and provides benefits like fee waivers and tax credits. Orphan drug approval comes later when your product is approved by FDA, unlocking 7 years of market exclusivity. Learn more about the orphan drug approval process.

When should I apply for orphan designation?

As soon as you generate an efficacy signal from in vivo animal model data. Applying early allows you to maximize regulatory benefits and increase asset value to support fundraising.

Does orphan designation guarantee approval?

No. Orphan designation provides development and economic incentives, but your product must still meet FDA's safety and efficacy standards for approval. However, the designation does signal FDA's recognition that your indication qualifies as a rare disease.

Guide to IND-Enabling Studies: Prep for Clinical Trials

Thu, 04 Dec 2025 17:22:26 GMT

What Are IND Applications For?

Before investigational drugs can be tested in humans, sponsors must obtain clearance from the U.S. Food and Drug Administration (FDA) through an Investigational New Drug (IND) application. This submission must include results from a series of nonclinical assessments, collectively known as IND-enabling studies, designed to demonstrate that it is reasonably safe to proceed to first-in-human (FIH) trials.

These foundational studies help drug developers:

Identify potential safety concerns early
Define safe starting doses and dosing ranges
Establish parameters for clinical monitoring

By guiding dose selection and ensuring a strong safety profile, IND-enabling studies are critical for risk mitigation in early development and setting the foundation for regulatory success.

What are IND-Enabling Studies?

IND-enabling studies encompass a range of in vitro and in vivo experiments that characterize a drug's pharmacologic and toxicologic properties. Together, these data support the scientific rationale for human exposure and ensure that the first clinical study is appropriately designed and justified.

Key Components of an IND-Enabling Program

The scope of IND-enabling studies depends on several factors, including the drug class, route of administration, duration of intended treatment, and target patient population. However, most programs include the following core elements:

Overview of Key Focus Areas:

Pharmacology and safety pharmacology — evaluation of the drug's intended mechanism of action as well as potential off-target effects on vital organ systems.
Pharmacokinetics (PK) — understanding how the drug is absorbed, distributed, metabolized, and excreted (ADME).
Toxicology — defining safe exposure limits, identifying potential adverse effects, and assessing reversibility of toxicity.

Pharmacology

Safety pharmacology studies evaluate a compound's effects on critical physiological systems (typically cardiovascular, respiratory, and central nervous systems) in relevant animal models. Primary pharmacodynamic studies also assess how the drug exerts its therapeutic effect, its dose-response relationship, and potential off-target activity.

Pharmacokinetics

Pharmacokinetics (PK) studies characterize the drug's exposure profile in animal species used for toxicity testing. These may include in vitro metabolism and plasma protein binding assessments as well as in vivo exposure and distribution studies. Together, these data inform the prediction of human pharmacokinetics and support the selection of safe, scientifically justified starting doses for Phase 1 trials.

More advanced PK work, such as radiolabeled mass balance studies, drug-drug interaction (DDI) evaluations, and metabolite profiling, is often completed later in development but may be initiated earlier depending on the molecule's complexity.

Toxicology

Toxicology studies form the cornerstone of IND-enabling packages. Sponsors generally conduct both acute (single-dose) and repeated-dose toxicity studies in two species (one rodent, one non-rodent) via clinically relevant administration routes. These studies help establish the no-observed-adverse-effect level (NOAEL) and maximum tolerated dose (MTD) —key parameters for dose selection in humans.

Genotoxicity evaluations, including assays for gene mutation and chromosomal damage, are typically required before first-in-human dosing and must be completed prior to Phase 2 trials. Additional studies—such as reproductive, immunotoxicity, and abuse liability testing—may be conducted as appropriate to the therapeutic indication and mechanism of action.

Moving Beyond IND Submission

IND-enabling studies support initial clinical entry, but continued nonclinical development may be needed. Many programs require long-term toxicity and carcinogenicity studies before late-phase or marketing applications. As programs progress, ongoing integration of nonclinical and clinical findings is essential for refining risk assessments and ensuring patient safety throughout development.

IND-Enabling Studies & Orphan Designation

IND-enabling studies are the catalyst of a successful drug development program. They validate safety for human exposure, guide early clinical design, and build the confidence regulators need to authorize in-human testing.

For sponsors pursuing orphan drug designation or preparing regulatory submissions across FDA and EMA pathways, a clear IND-enabling strategy is essential to staying on schedule and minimizing costly setbacks.

Only Orphans Cote supports sponsors developing rare-disease therapies in achieving market authorization with the greatest economic benefit. Since the IND is one of the most critical milestones in drug development, OOC helps turn strong science into practical, successful regulatory outcomes.

Contact us to discuss how our team can support your orphan designation strategy in parallel with IND preparation.

Top Reasons FDA Issues Deficiency Letters for Orphan Drug Designation (ODD) Applications

Thu, 13 Nov 2025 16:48:46 GMT

The FDA is highly supportive of orphan drug development, but that doesn’t mean every Orphan Drug Designation (ODD) application gets approved on the first review cycle. Many sponsors still end up with deficiency letters—and they tend to focus on the same trouble spots: not enough indication-specific medical rationale or prevalence estimates that don’t fully add up.

Most of these issues aren’t hard to fix once you know what FDA is looking for. Read on for a breakdown of the most common reasons applications are flagged to help your application get approved on the first try.

1. Medical Rationale Not Qualified

The majority of ODD deficiencies stem from inadequate scientific evidence supporting the drug’s potential efficacy in the rare indication.

Lack of Appropriate In-Vivo Efficacy Data

In-vitro data alone is insufficient. FDA expects in-vivo animal data that reflects the specific human disease.
Model relevance matters. The animal model must be well-established and recognized in peer-reviewed literature for that particular indication.
Disease stage timing. Data must show treatment efficacy after disease manifestation, not just prevention.

Poorly Defined or Unsupported Models

Using a general model not validated for the target indication.
No citation or insufficient evidence that the model mimics human pathophysiology.

Clinical Data Not Demonstrating Indication-Specific Effect

Case reports may suffice in rare instances, but must clearly demonstrate drug benefit for the exact indication.
Anecdotal or uncontrolled data without disease-specific context are not acceptable.

2. Prevalence Data Not Qualified

The second most common cause involves errors or omissions in demonstrating that the target patient population in the U.S. is below 200,000.

Underestimating or Misquoting Literature Data

Sponsors often cite outdated or narrow studies. FDA expects use of the highest credible prevalence estimate found in peer-reviewed sources.

Failure to Establish a Valid Orphan Subset

When applying for an orphan subset of a common disease, the sponsor must show the drug is not effective outside that subset.
Mechanistic or pharmacologic rationale should clearly limit the activity to the defined rare group.

Unclear or Improperly Defined Indication

FDA retains discretion to determine what constitutes a unique “disease or condition.”
Sponsors must align indication wording with FDA precedent and guidance.
The only reliable way to verify whether an indication qualifies as a valid orphan disease is by checking the FDA Orphan Drug Designation Database (https://www.accessdata.fda.gov/scripts/opdlisting/oopd/). However, note that past designations may no longer reflect current prevalence data.

Need Support With Your ODD Submission?

The deficiency letter is a highly informative resource. If you want to avoid setbacks and another 90-day review delay (now extended due to staffing shortages and government slowdowns) contact Only Orphans Cote for a complimentary review of your FDA ODD deficiency letter . Our 95% first-attempt FDA application success rate reflects our expertise with each and every ODD application.

FDA ODD Deficiency Letter FAQs

The Benefits of Orphan Drug Designation and Market Exclusivity

Thu, 30 Oct 2025 18:10:35 GMT

Orphan Drug Designation (ODD) is one of the earliest and most essential regulatory steps for sponsors developing therapies for rare diseases. For eligible products, this designation opens the door to significant financial, regulatory, and strategic advantages that can shape the success of an entire development program.

What is Orphan Drug Designation?

The Orphan Drug Act of 1983 was created to stimulate the development of treatments for rare diseases: conditions affecting fewer than 200,000 people in the United States. Since its enactment, approvals for rare disease drugs have surged from fewer than 10 before 1983 to over 1,100 today, as thousands of sponsors have pursued this pathway to bring new hope to patients.

Receiving orphan drug designation (ODD) from the FDA confirms that your therapy addresses a rare disease and meets eligibility criteria for specialized regulatory incentives. An orphan drug designation does not mean the drug is approved yet, but it is a major strategic milestone. It opens access to valuable FDA incentives that can significantly ease the cost, risk, and timeline of later development and approval.

The Four Legal Benefits of FDA Orphan Drug Designation

The four core benefits written into The Orphan Drug Act of 1983 are:

Orphan Drug Exclusivity – 7 years of protection against approval of the same drug for the same indication (in the U.S.)
Tax Benefits – Up to 25% tax credit on qualified U.S. clinical trial expenses.
Exemption from PDUFA Fees – Waiver of the FDA’s Prescription Drug User Fee Act (PDUFA) fee, which is over $4.3 million per application.
Exemption from PREA – The Pediatric Research Equity Act normally requires pediatric studies for new drugs, but orphan drugs are exempt from this obligation.

Those are the tangible, statutory benefits—but the strategic advantages extend even further. As Dr. Tim Cote, former Director of the FDA’s Office of Orphan Products and CEO of Only Orphans Cote, explains:

“In practice, orphan designation makes your program more fundable and your trials easier to enroll,” says Dr. Cote. “That’s the real-world value every sponsor feels.”

When to Apply for Orphan Designation

Sponsors often ask: When is the right time to apply?
Dr. Cote’s answer is simple: “The first moment you are eligible. As soon as you have the medical rationale and preliminary data in hand, apply.”

Once you obtain efficacy data from an in-vivo animal model relevant to the human rare disease, you become eligible to apply for ODD. Alternatively, case reports from 2–3 patients may also support eligibility if you are already in the clinical stage.

What is Orphan Drug Market Exclusivity?

Orphan drug market exclusivity is the period of time after approval during which the FDA will not approve another sponsor’s application for the same drug for the same rare disease or condition.

As Dr. Tim Cote explains, orphan drug exclusivity is based on a “dyad”—the combination of a specific drug and a specific disease. The designation itself doesn’t grant exclusivity; it simply defines that dyad.

Multiple Sponsors, Same Designation, One Exclusivity Winner

Multiple companies can hold the same orphan designation for the same drug–disease pair, but only the first sponsor to achieve marketing approval wins exclusivity. That sponsor receives seven years of protection in the U.S. (and ten in the EU), during which competitors cannot market the same drug for that indication unless they prove it is clinically superior .

“It’s a horse race,” says Dr. Cote. “Many can line up with the same designation, but the first to cross the finish line—marketing authorization—gets the exclusivity. Winner takes all.”

Key Takeaways

Orphan drug designation benefits include exclusivity, tax credits, fee exemptions, and regulatory flexibility.
Orphan exclusivity protects the approved therapy for seven years in the U.S.—awarded to the first sponsor to reach marketing authorization.
The best time to apply is as soon as eligibility criteria are met.
Beyond statutory benefits, designation increases visibility, funding potential, and partnership opportunities for rare disease programs.

How Only Orphans Cote Can Help

Founded and led by Dr. Tim Cote, former FDA Director of the Office of Orphan Products, Only Orphans Cote specializes in helping sponsors navigate the orphan designation process from eligibility analysis through FDA or EMA submission.

We guide sponsors through:

Determining whether your drug qualifies for orphan designation
Preparing the scientific rationale and prevalence data
Writing and submitting a complete, compliant designation request to the FDA and/or EMA
Strategically positioning your program for regulatory success

Contact us to discuss your orphan drug program and learn how our experts can help you secure designation faster and move confidently toward market authorization.

Orphan Drug Designation Frequently Asked Questions

FDA Introduces Rare Disease Evidence Principles (RDEP) to Advance Orphan Drug Development

Thu, 02 Oct 2025 16:01:34 GMT

The FDA's New Rare Disease Evidence Principles

The U.S. Food and Drug Administration (FDA) has introduced the Rare Disease Evidence Principles (RDEP), a new framework designed to provide greater clarity and predictability for drug developers pursuing therapies for rare diseases. The program is intended for therapies addressing small patient populations (generally <1,000 patients in the US) with urgent unmet medical needs caused by known genetic defects.

What Is the Rare Disease Evidence Principles (RDEP) Framework?

Drug developers in the rare disease sector often face the challenge of generating “substantial evidence” of safety and efficacy through traditional multi-trial clinical programs. For many rare conditions, recruiting sufficient patient numbers to run multiple large-scale studies is either extremely difficult or impossible.

The RDEP was jointly developed by the FDA’s Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) to address these challenges. Under this framework, sponsors may qualify for FDA approval based on one adequate and well-controlled study plus robust confirmatory evidence, which may include:

Strong mechanistic or biomarker data
Evidence from relevant non-clinical models
Clinical pharmacodynamic data
Case reports, expanded access data, or natural history studies
Sponsors can apply for review under the RDEP process before launching a pivotal trial, with patient and expert input encouraged throughout the process.

Eligibility Criteria

The RDEP applies only to therapies that:

Target a very small patient population (generally <1,000 U.S. patients)
Address a serious or life-threatening rare disease caused by a known genetic defect
Are intended for patients facing rapid deterioration in function, disability, or death
Lack adequate existing treatment alternatives

Therapies developed for rare cancers may also be eligible, though sponsors must first consult with the Oncology Center of Excellence or the relevant FDA review division.

Postmarketing Requirements

Drugs approved under the RDEP may be subject to additional postmarketing obligations to further confirm safety and effectiveness once therapies are available to patients.

RDEP vs. Orphan Drug Designation

It is important to note that the RDEP review is independent of orphan drug designation under section 526 of the Federal Food, Drug & Cosmetic Act. A therapy evaluated under the RDEP framework does not automatically qualify for orphan drug designation, and sponsors seeking designation must still follow the established orphan application process under 21 C.F.R. Part 316.

Next Steps for Sponsors

Sponsors may request review under the RDEP by submitting a formal meeting request to the FDA before beginning pivotal trials. Clearer FDA guidance under this process aims to reduce uncertainty and streamline development timelines for therapies in populations with the greatest need.

What RDEP Means in Practice

Dr. Tim Cote, former FDA Director of the Office of Orphan Products Development and Founder of Only Orphans Cote , provides this perspective:

The RDEP program represents a revolutionary shift in how the FDA approaches ultra-rare diseases. No longer is the same “substantial safety and efficacy” standard applied across all diseases, regardless of prevalence. Under RDEP, efficacy evidence can be viewed in a completely new light: if there is a clear genetic or pathophysiological pathway, a biomarker-measurable endpoint, and a supporting animal model, the FDA can now move to full marketing authorization even with very limited human data.

Not all stakeholders are convinced. Critics have labeled the program “all wrapper and no gift,” often pointing to the strict prevalence threshold of fewer than 1,000 U.S. patients. However, at Only Orphans Cote, we see this as a radical improvement for developers tackling ultra-rare conditions. While we may not align with every policy shift at the FDA, we believe that with RDEP, they got it right.

Key Takeaway

The FDA’s new Rare Disease Evidence Principles represent a significant step forward for developers working in rare disease spaces where traditional clinical development is not feasible. By clarifying acceptable forms of confirmatory evidence and opening a more predictable pathway to approval, the FDA aims to accelerate safe, effective therapies for some of the most underserved patient populations.

Partner with Experts Who Know the FDA

Navigating new FDA frameworks like RDEP requires experience, strategy, and credibility. At Only Orphans Cote, we’ve guided countless sponsors through orphan drug designations, expedited pathways, and FDA meetings—with a proven track record of success.

Whether you’re considering RDEP or weighing other regulatory strategies, our team can help you assess eligibility, prepare a strong request, and align your development program for approval.

Contact Only Orphans Cote today to schedule a consultation with Dr. Tim Cote and our regulatory experts.

Reference

U.S. Food and Drug Administration. FDA Advances Rare Disease Drug Development with New Evidence Principles. News Release. September 3, 2025. Available at: https://www.fda.gov/news-events/press-announcements/fda-advances-rare-disease-drug-development-new-evidence-principles

Orphan Drug Insights Journal

Orphan Drug Designation by the European Medicines Agency (EMA ODD)

What to Know About Orphan Drug Designation in Europe

EMA Orphan Designation Criteria

Who Reviews the Application

A Cautionary Case Study: Tissue-Agnostic Indications

How to Apply for EMA Orphan Designation

Incentives for EMA Orphan Designation

EMA vs. FDA for Orphan Drug Designation

﻿ How Only Orphans Cote Supports Sponsors Pursuing EMA Designation

Conclusion

FAQs

Expedited Programs Beyond Orphan Designation

Four Expedited Drug Approval Programs

1. Priority Review

2. Accelerated Approval

3. Fast Track Designation

4. Breakthrough Therapy

What Are the Benefits of Expedited Programs?

The Benefits

Conclusion

FAQs

What is the difference between orphan drug designation and the four expedited programs?

Can a drug qualify for more than one expedited program?

When should a sponsor request expedited designation?

What is a surrogate endpoint for Accelerated Approval purposes?

﻿

A Win for Rare Pediatric Disease Drug Innovation: The RPDD & PRV Program Is Reauthorized Through 2029, and OOC Is Ready

What Are RPDD and PRV?

A Program With Deep Roots, and OOC's Fingerprints on It

The Numbers Speak for Themselves

What the Consolidated Appropriations Act of 2026 Actually Does

RPDD PRV Program Reauthorized Through September 30, 2029

How OOC Helps You Navigate the RPDD PRV Lifecycle

Let's Talk

﻿

Tropical Disease Priority Review Vouchers (PRVs) - How They Work

What Is a Tropical Disease PRV?

How to Qualify for a Tropical Disease PRV

1. Treats or Prevents a Listed Tropical Disease

2. Independently Qualifies for Priority Review

3. Contains No Previously Approved Active Ingredients

4. Includes a New Clinical Investigation (Post-2017 Applications)

5. Provides Required Attestations

Which Tropical Diseases Qualify?

Why Tropical Disease PRVs Matter

How Sponsors Should Evaluate PRV Eligibility

No Separate Application Required

Common Misconceptions

Get Expert Guidance

Frequently Asked Questions

What is a Tropical Disease Priority Review Voucher worth?

Can I apply for a tropical disease PRV separately from my drug approval?

Can a product qualify for both orphan designation and a tropical disease PRV?

What happens if my product doesn't qualify for priority review on its own merits?

Are tropical disease PRVs transferable?

What's the difference between a tropical disease PRV and a rare pediatric disease PRV?

When should I start planning for PRV eligibility in my development program?

FDA Orphan Drug Designation for Rare Cancers: U.S. Eligibility Guide

Understanding FDA Incentives for Rare Conditions - Eligible Cancers

The Rare Cancer Landscape: Broader Than You Think

How FDA Determines If a Cancer Is "Rare"

Which Cancers Typically Qualify as Rare?

Rare Cancers:

Common Cancers (Generally Don't Qualify):

The Critical U.S.-Only Prevalence Rule: The Most Overlooked Opportunity

Why This Matters: Globally Common Cancers May Still Qualify

Real-World Examples of This Overlooked Opportunity

The Strategic Implication

What Orphan Designation Unlocks

Common Mistakes Sponsors Make

Work With Experts Who Know FDA from the Inside

Frequently Asked Questions

Does global prevalence matter for FDA orphan designation?

Can a subset of a common cancer qualify for orphan designation?

What if my cancer is common in some countries but rare in the U.S.?

What's the difference between orphan designation and orphan drug approval?

When should I apply for orphan designation?

Does orphan designation guarantee approval?

Guide to IND-Enabling Studies: Prep for Clinical Trials

How Only Orphans Cote Supports Sponsors Pursuing EMA Designation